GO
Gossamer Bio, Inc.
GOSS · NASDAQ
$10.38 -2.17% (-$0.23)
1M -7.32%
Market Cap $63.4M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$7.48
27.9% downside
Current Price
$10.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GOSS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 1.19x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 99.56%
Net margin 235.00%
Op. margin 311.70%
Quality
70 /100
Excellent ROIC 670.05%
ROA 162.91%
Asset turnover 0.69x
Debt
3 /100
High Current ratio 0.53x
Int. coverage -18.75x
Debt/Equity N/A
Stability
1 /100
Unstable Beta 2.00x
EPS volatility 155.43%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GOSS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Faheem Hasnain
Employees
162
Headquarters
San Diego
Upcoming events
04 NOV
Earnings
Upcoming earnings report